

Table SI. Multivariate analysisfordelayed MTX elimination

Characteristics	Adjusted odds ratio	95% CI	P-value
$C_{24} \geq 10 \mu\text{mol/l}$			
Dosing regimen (BSA/PK)	3.534	1.326-9.434	0.012
Age, years (continuous)	1.048	1.018-1.079	0.001
Gender (female/male)	0.840	0.287-2.459	0.751
Creatinine clearance, ml/min(continuous)	1.000	0.991-1.010	0.968
Dosage of MTX, g (continuous)	1.124	0.918-1.377	0.257
$C_{48} \geq 1 \mu\text{mol/l}$			
Dosing regimen (BSA/PK)	8.065	2.020-32.29	0.003
Age, years (continuous)	1.035	0.995-1.075	0.084
Gender (female/male)	1.029	0.249-4.246	0.969
Creatinine clearance, ml/min(continuous)	1.006	0.994-1.018	0.339
Dosage of MTX, g (continuous)	0.827	0.618-1.106	0.200
$C_{72} \geq 0.1 \mu\text{mol/l}$			
Dosing regimen (BSA/PK)	2.299	1.107-4.762	0.025
Age, years (continuous)	1.040	1.017-1.064	0.001
Gender (female/male)	0.534	0.271-1.051	0.069
Creatinine clearance, ml/min(continuous)	0.996	0.990-1.002	0.226
Dosage of MTX, g (continuous)	1.067	0.950-1.197	0.273

The data were analyzed using binomial logistic regression. MTX, methotrexate; CI, confidence interval; BSA, body surface area; PK, pharmacokinetics; C_{24} , C_{48} , and C_{72} , concentrations at 24, 48, and 72 h after the start of methotrexate infusion, respectively.

Table SII. Multivariate analysis for adverse events.

Characteristics	Adjusted odds ratio	95% CI	P-value
Grade ≥ 2 AST increased			
Dosing regimen (BSA/PK)	2.941	1.404-6.173	0.004
Age, years (continuous)	0.962	0.938-0.986	0.002
Gender (female/male)	3.307	1.768-6.186	<0.001
Creatinine clearance, ml/min (continuous)	0.997	0.991-1.003	0.315
Dosage of MTX, g (continuous)	1.053	0.939-1.181	0.379
Grade ≥ 2 ALT increased			
Dosing regimen (BSA/PK)	3.205	1.490-6.897	0.003
Age, years (continuous)	0.969	0.946-0.991	0.007
Gender (female/male)	5.475	2.848-10.525	<0.001
Creatinine clearance, ml/min (continuous)	1.001	0.995-1.007	0.816
Dosage of MTX, g (continuous)	1.028	0.918-1.152	0.633

The data were analyzed using binomial logistic regression. CI, confidence interval; BSA, body surface area; PK, pharmacokinetics; MTX, methotrexate; AST, aspartate aminotransferase; ALT, alanine aminotransferase.